In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
1. An isolated non-lipidated and non-pyruvylated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 70.
2. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 71, wherein an N-terminal cysteine at position 1 is deleted, as compared to SEQ ID NO: 70.
3. The polypeptide according to claim 1 , wherein the polypeptide is immunogenic.
4. The polypeptide according to claim 1 , wherein the polypeptide does not exhibit a mass shift of about +70 Da compared to the corresponding non-lipidated polypeptide as measured by mass spectrometry.
5. The isolated polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence at position 1-184 of SEQ ID NO: 71.
6. The isolated polypeptide according to claim 1 , wherein the amino acid sequence consists of the sequence set forth in SEQ ID NO: 71.
7. An immunogenic composition comprising the polypeptide as in any of claims 1 2 - 5 , and 6 .
8. The immunogenic composition according to claim 1 , further comprising an isolated non-lipidated and non-pyruvylated polypeptide having the amino acid sequence set forth in SEQ ID NO: 49, wherein an N-terminal cysteine at position 1 is deleted as compared to SEQ ID NO: 18.